Bevacizumab combination improves survival in advanced NSCLC

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1492, 2005-01, pp. : 17-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cisplatin-based adjuvant therapy improves survival in NSCLC

Inpharma, Vol. 1, Iss. 1422, 2004-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Erlotinib prolongs survival in advanced, refractory NSCLC

Inpharma, Vol. 1, Iss. 1444, 2004-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Strontium-89 improves survival in advanced prostate cancer

Inpharma, Vol. 1, Iss. 1274, 2001-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Bank on bevacizumab to save money in NSCLC

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 580, 2009-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Erlotinib improves QOL in NSCLC

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 512, 2006-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite